These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8132855)

  • 1. Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted?
    Rowland MJ; Bransome ED; Hendry LB
    J Clin Pharmacol; 1994 Jan; 34(1):80-5. PubMed ID: 8132855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.
    Ito D; Amano T; Sato H; Fukuuchi Y
    J Neurol; 2001 Jun; 248(6):533-4. PubMed ID: 11499649
    [No Abstract]   [Full Text] [Related]  

  • 3. A hypertensive reaction induced by concurrent use of selegiline and dopamine.
    Rose LM; Ohlinger MJ; Mauro VF
    Ann Pharmacother; 2000 Sep; 34(9):1020-4. PubMed ID: 10981248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

  • 7. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 8. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
    LeWitt PA
    Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
    [No Abstract]   [Full Text] [Related]  

  • 9. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
    Lew MF
    Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 11. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ
    J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAO-B inhibitors in Parkinson's disease.
    Olanow CW
    Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
    [No Abstract]   [Full Text] [Related]  

  • 16. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 17. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term selegiline tolerance in the treatment of Parkinson's disease].
    Vermersch P; Petit H
    Therapie; 1992; 47(1):75-8. PubMed ID: 1523599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine and selegiline--lack of significant interaction.
    Waters CH
    Can J Neurol Sci; 1994 Aug; 21(3):259-61. PubMed ID: 8000982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.